Clinical application of base editing for treating β-thalassaemia

Cao, A. & Galanello, R. Beta-thalassemia. Genet. Med. 12, 61–76 (2010).

Origa, R. Beta-thalassemia. Genet. Med. 19, 609–619 (2017).

Taher, A. T., Musallam, K. M. & Cappellini, M. D. β-Thalassemias. N. Engl. J. Med. 384, 727–743 (2021).

Hardouin, G., Miccio, A. & Brusson, M. Gene therapy for β-thalassemia: current and future options. Trends Mol. Med. https://doi.org/10.1016/j.molmed.2024.12.001 (2025).

Wang, L. et al. Eliminating base-editor-induced genome-wide and transcriptome-wide off-target mutations. Nat. Cell Biol. 23, 552–563 (2021).

Han, W. et al. Design and application of the transformer base editor in mammalian cells and mice. Nat. Protoc. 18, 3194–3228 (2023).

Han, W. et al. Base editing of the HBG promoter induces potent fetal hemoglobin expression with no detectable off-target mutations in human HSCs. Cell Stem Cell 30, 1624–1639 (2023).

Galanello, R. & Origa, R. Beta-thalassemia. Orphanet J. Rare Dis. 5, 11 (2010).

Thein, S. L. The molecular basis of β-thalassemia. Cold Spring Harb. Perspect. Med. 3, a011700 (2013).

Cavazzana-Calvo, M. et al. Transfusion independence and HMGA2 activation after gene therapy of human β-thalassaemia. Nature 467, 318–322 (2010).

... continue reading